Although we previously observed that inhibition of immunoproteasome LMP2 by shRNA reduced infarction volumes and improved the neurologic recovery in rats after 14 days ischaemia/reperfusion,11 the neurological deficit results of these genetic and pharmacological manipulations after stroke did not provide in this study. The gene discussed is PSMB9; the disease is stroke disorder.